BD, 565641, Purified Mouse Anti-Human LDLR C7 (also known as IgG-C7)

The C7 monoclonal antibody specifically binds to the low-density lipoprotein (LDL) receptor, a type I membrane protein that is encoded by the LDLR gene. LDL is the major cholesterol-carrying lipoprotein in plasma. Cell surface LDLR controls the level of cholesterol in plasma by binding to and internalizing LDL and transporting it to lysosomes where LDL is degraded, cholesterol is released into the cell, and LDLR is recycled back to the cell surface. Hence LDLR is found in cell-surface and intracellular membranes (eg, clathrin-coated pits, golgi, endosomes, and lysosomes). Expression of LDLR is a marker for in vitro differentiation of hepatocytes from human embryonic stem cells. LDLR is suspected to mediate infections by viruses that associate with lipoprotein in the blood. Mutations in LDLR are largely responsible for Familial Hypercholesterolemia (FH). The C7 monoclonal antibody has been reported to react with bovine and human LDLR, but not LDLRs of mouse, rat, Chinese hamster, rabbit or dog.

Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Sodium azide is a reversible inhibitor of oxidative metabolism; therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
5. An isotype control should be used at the same concentration as the antibody of interest.